From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM-Reference-Cited by-同舟云学术

From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM

Published:2004-01 Issue:1 Volume:6 Page:23-32
ISSN:1462-5814
Container-title:Cellular Microbiology
language:en
Short-container-title:

Author:

Lycke Nils

Publisher

Hindawi Limited

Subject

Virology,Immunology,Microbiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1462-5822.2003.00338.x/fullpdf

Reference61 articles.

1. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit;Agren;J Immunol,1997

2. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity;Agren;J Immunol,1999

3. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects;Agren;J Immunol,2000

4. Control of adaptive immune responses by Toll-like receptors;Barton;Curr Opin Immunol,2002

5. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant;Choi;Vaccine,2002

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potentials of saponins-based adjuvants for nasal vaccines;Frontiers in Immunology;2023-03-20

2. Adjuvant effect of enterotoxigenic Escherichia coli (ETEC) double-mutant heat-labile toxin (dmLT) on systemic immunogenicity induced by the CFA/I/II/IV MEFA ETEC vaccine: Dose-related enhancement of antibody responses to seven ETEC adhesins (CFA/I, CS1-CS6);Human Vaccines & Immunotherapeutics;2019-08-23

3. Intranasal inoculate of influenza virus vaccine against lethal virus challenge;Vaccine;2018-07

4. An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy;Trends in Pharmacological Sciences;2017-09

5. Lipophilic peptide character – What oral barriers fear the most;Journal of Controlled Release;2017-06